This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Look: Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity with an Oncologist

Ticker(s): LLY, NVO

Who's the expert?

Institution: Self-employed

  • Board Certified Hematologist and Medical Oncologist in private practice since 2011
  • treats 25 patients for B-Cell Non-Hodgkin’s Lymphoma, 10 of whom have the diffuse large B-cell lymphoma (DLBCL) subtype

Interview Goal
This interview will focus on a recent study that hypothesized that GLP-1RAs are associated with a decreased risk for CRC in patients with T2D compared with non–GLP-1RA antidiabetics (published in JAMA Oncology).

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.